Key result
SEA0400 selectively inhibits plasmalemmal NCX while CGP-37157 targets mitochondrial NCX in intact cardiomyocytes.
Why the study?
Pharmacological discrimination between plasmalemmal and mitochondrial sodium–calcium exchangers in cardiomyocytes was unclear.
SEA0400 and CGP-37157 act as selective inhibitors for plasmalemmal and mitochondrial NCX respectively, providing pharmacological evidence that they are distinct molecular entities.
Answers are grounded in this paper and cite their sources.
Supports distinct plasmalemmal and mitochondrial NCX entities; leaves open in vivo cardiac translation.
We examined the effects of SEA0400 and CGP-37157 on the plasmalemmal Na(+)-Ca(2+) exchanger (NCX) and mitochondrial NCX using H9c2 cardiomyocytes loaded with Ca(2+)-sensitive fluorescent probes. The plasmalemmal NCX activity, which was measured as the increase in cytoplasmic Ca(2+) concentration after application of low Na(+) extracellular solution, was inhibited by SEA0400 but not by CGP-37157. The mitochondrial NCX activity, which was measured in permeabilized H9c2 cells as the decrease in mitochondrial Ca(2+) concentration after application of Ca(2+)-free extramitochondrial solution, was inhibited by CGP-37157 but not by SEA0400. These results indicate that SEA0400 and CGP-37157 act as selective inhibitors towards plasmalemmal and mitochondrial NCX, respectively, and provide pharmacological evidence that the plasmalemmal and mitochondrial NCX are distinct molecular entities.
No takes yet. Share an insight, caveat, or question.
Namekata et al. (2015) studied In vitro cardiomyocyte study. SEA0400 and CGP-37157 vs. Control (absence of inhibitors) was evaluated on Plasmalemmal and mitochondrial NCX activity (measured by cytoplasmic and mitochondrial Ca2+ concentrations). SEA0400 selectively inhibited plasmalemmal NCX, while CGP-37157 selectively inhibited mitochondrial NCX in intact cardiomyocyte-derived H9c2 cells.
Synapse has enriched 10 related papers. Consider them for comparative context: